The investigational drug, called PMD-026, is currently in phase 2 clinical trials for the treatment of breast cancer.

The global hematology diagnostic market is projected to grow from USD 780.0 million in 2023 to USD 2.0 billion by 2033, at a ...

Two new studies led by researchers at Washington University School of Medicine in St. Louis have identified a possible way to block the progression of several forms of blood cancer using a drug ...

A group of immune proteins called the inflammasome can help prevent blood stem cells from becoming malignant by removing ...

Humans and mice exposed to long-wavelength red light had lower rates of blood clots that can cause heart attacks, lung damage and strokes, according to research led by surgeon-scientists.

A team of researchers from the Translational Oncology Research Centre (TORC) of Vrije Universiteit Brussel (VUB), in ...

Adaptive Biotechnologies Corporation (Nasdaq:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and ...

The phase 2 trial showed a 42% response rate with lete-cel in synovial sarcoma and MRCLS, with manageable adverse events.

Cell therapies — particularly chimeric antigen receptor T-cell (CAR T) therapies — have shown remarkable efficacy in treating ...

More Than 40 Adult Sickle Cell Disease Patients Now Enrolled in BEACON Trial of BEAM-101; Beam Expects to Dose 30 Patients and Present Updated ...

Beam is pursuing a long-term, staged development strategy for sickle cell disease that includes three “waves” of ...